换一批
换一批
作者：
Marta,Castroviejo-Bermejo [1]
;
Cristina,Cruz [1]
;
Alba,Llop-Guevara [2]
;
Sara,Gutiérrez-Enríquez [3]
;
Mandy,Ducy [1]
;
Yasir Hussein,Ibrahim [4]
;
Albert,Gris-Oliver [5]
;
Benedetta,Pellegrino [6]
;
Alejandra,Bruna [7]
;
Marta,Guzmán [1]
;
Olga,Rodríguez [1]
;
Judit,Grueso [1]
;
Sandra,Bonache [8]
;
Alejandro,Moles-Fernández [9]
;
Guillermo,Villacampa [1]
;
Cristina,Viaplana [1]
;
Patricia,Gómez [1]
;
Maria,Vidal [4]
;
Vicente,Peg [4]
;
Xavier,Serres-Créixams [10]
;
Graham,Dellaire [10]
;
Jacques,Simard [3]
;
Paolo,Nuciforo [11]
;
Isabel T,Rubio [3]
;
Rodrigo,Dienstmann [11]
;
J Carl,Barrett [12]
;
Carlos,Caldas [13]
;
José,Baselga [14]
;
Cristina,Saura [15]
;
Javier,Cortés [7]
;
Olivier,Déas [13]
;
Jos,Jonkers [16]
;
Jean-Yves,Masson [13]
;
Stefano,Cairo [17]
;
Jean-Gabriel,Judde [10]
;
Mark J,O'Connor [18]
;
Orland,Díez [9]
;
Judith,Balmaña [19]
;
Violeta,Serra [20]
作者单位：
Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
[1]
High Risk and Familial Cancer Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
[2]
Department of Medical Oncology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
[3]
Oncogenetics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
[4]
Genome Stability Laboratory, CHU de Québec Research Center, Québec City, QC, Canada.
[5]
Department of Molecular Biology, Medical Biochemistry and Pathology, Laval University Cancer Research Center, Québec City, QC, Canada.
[6]
CHU de Quebec - Université Laval Research Center, Genomics Center CHUL, Québec City, QC, Canada.
[7]
Department of Medical Oncology, University Hospital of Parma, Parma, Italy.
[8]
Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.
[9]
Oncology Data Science (OdysSey Group), Vall d'Hebron Institute of Oncology, Barcelona, Spain.
[10]
Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
[11]
Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
[12]
CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
[13]
Department of Radiology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
[14]
Department of Pathology, Dalhousie University, Halifax, NS, Canada.
[15]
Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
[16]
Breast Surgical Unit, Breast Cancer Center, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
[17]
AstraZeneca, Waltham, MA, USA.
[18]
Breast Cancer Programme, Cancer Research UK (CRUK) Cambridge Cancer Centre, Cambridge, UK.
[19]
Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, New York, NY, USA.
[20]
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
[21]
Department of Oncology, Ramón y Cajal University Hospital, Madrid, Spain.
[22]
Vall d'Hebron Institute of Oncology, Barcelona, Spain.
[23]
XenTech, Evry, France.
[24]
Division of Molecular Pathology and Cancer Genomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
[25]
Oncology Innovative Medicines and Early Clinical Development Biotech Unit, AstraZeneca, Cambridge, UK.
[26]
Clinical and Molecular Genetics Area, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
[27]
High Risk and Familial Cancer Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain jbalmana@vhio.net vserra@vhio.net.
[28]
Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain jbalmana@vhio.net vserra@vhio.net.
[29]
主题词
动物(Animals);抗肿瘤药(Antineoplastic Agents);乳腺肿瘤(Breast Neoplasms);抗药性, 肿瘤(Drug Resistance, Neoplasm);女(雌)性(Female);人类(Humans);小鼠(Mice);酞嗪类(Phthalazines);哌嗪类(Piperazines);Rad51重组酶(Rad51 Recombinase)
DOI
10.15252/emmm.201809172
PMID
30377213
发布时间
2024-03-20
- 浏览2
EMBO molecular medicine
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
